Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of YYC405-T Added to Metformin and Dapagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With the Combination of Metformin and Dapagliflozin

Phase 3 study to assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

Phase 3 study to assess the Efficacy and Safety of YYC405-T when added to Metformin and Dapagliflozin combination therapy in patients with type 2 diabetes mellitus who have inadequate glycemic control

Inclusion Criteria:

• Patient who contsent to participate in this tiral by written informed consent form
• A man or woman over 20 years old
• Type 2 Diabetes patients

Exclusion Criteria:

• Patients with severe renal impairment, end-stage renal disease or on dialysis
• Type 1 diabetes patients
• Patients with a history of acute or chronic target acidosis, including lactic acidosis and diabetic ketoacidosis